PE20201280A1 - Amidas de imidazopiridina sustituidas y su uso - Google Patents

Amidas de imidazopiridina sustituidas y su uso

Info

Publication number
PE20201280A1
PE20201280A1 PE2020000420A PE2020000420A PE20201280A1 PE 20201280 A1 PE20201280 A1 PE 20201280A1 PE 2020000420 A PE2020000420 A PE 2020000420A PE 2020000420 A PE2020000420 A PE 2020000420A PE 20201280 A1 PE20201280 A1 PE 20201280A1
Authority
PE
Peru
Prior art keywords
diseases
heteroaromatic
solvates
salts
amino
Prior art date
Application number
PE2020000420A
Other languages
English (en)
Inventor
Daniel Meibom
Jutta Meyer
Karl Collins
Hernandez Nuria Ortega
Jan Stampfuss
Frank Wunder
Till Freudenberger
Thomas Mondritzki
Nina Alexandra Scheerer
Kirsten Leineweber
Jens Schamberger
Alexander Straub
Kersten Matthias Gericke
Walter Kroh
Mario Lobell
Klaus Munter
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20201280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20201280A1 publication Critical patent/PE20201280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referido a un compuesto de formula I, en la que A es un aza-heteroaromatico con carga positiva; en las que indica el punto de union, R1, R2, y R3a, R3b independientemente uno de otro, son un radical seleccionado del grupo que consiste en H, amino, (C1-C4)-alquilo, entre otros; R4 es (C1-C4)-alquilo, que puede ser sustituido hasta cinco veces por fluor, o es un grupo de la formula CH2CN, CH2CONH2; D es un heteroaromatico; L es CH2; n es el numero 0, 1, 2 o 3; y X? es un anion fisiologicamente aceptable; o los solvatos, sales y solvatos de las sales. Un compuesto seleccionado es: Formiato de 4-(dimetilamino)-1-[2-({[3-(3,5-dimetil-1,2-oxazol-4-il)imidazo[1,2-a]piridina-7-il]carbonil}amino)etil]piridinio. Estos compuestos son amidas de imidazopiridinas sustituidas, y son antagonistas de adrenoreceptor ?-2B (ADRA2B). Tambien se refiere a un procedimiento para la preparacion de dichos compuestos, composicion farmaceutica que los contiene, por si solos o en combinacion con otros, para el tratamiento y / o la profilaxis de enfermedades, tales como enfermedades cardiovasculares, neurologicas y del sistema nervioso central, asi como enfermedades metabolicas; y debido a su buena solubilidad, son adecuados para formas de administracion parenteral.
PE2020000420A 2017-10-24 2018-10-18 Amidas de imidazopiridina sustituidas y su uso PE20201280A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24
PCT/EP2018/078653 WO2019081353A1 (de) 2017-10-24 2018-10-18 Substituierte imidazopyridinamide und ihre verwendung

Publications (1)

Publication Number Publication Date
PE20201280A1 true PE20201280A1 (es) 2020-11-24

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000420A PE20201280A1 (es) 2017-10-24 2018-10-18 Amidas de imidazopiridina sustituidas y su uso

Country Status (27)

Country Link
US (1) US20200339567A1 (es)
EP (1) EP3700903A1 (es)
JP (1) JP2021500366A (es)
KR (1) KR20200076686A (es)
CN (1) CN111225917A (es)
AR (1) AR113790A1 (es)
AU (1) AU2018354785A1 (es)
BR (1) BR112020007967A2 (es)
CA (1) CA3084422A1 (es)
CL (1) CL2020001075A1 (es)
CO (1) CO2020004968A2 (es)
CR (1) CR20200173A (es)
CU (1) CU20200041A7 (es)
DO (1) DOP2020000072A (es)
EA (1) EA202091020A1 (es)
EC (1) ECSP20023043A (es)
IL (1) IL273954A (es)
JO (1) JOP20200073A1 (es)
MA (1) MA50440A (es)
MX (1) MX2020004190A (es)
NI (1) NI202000029A (es)
PE (1) PE20201280A1 (es)
PH (1) PH12020550472A1 (es)
SG (1) SG11202003641RA (es)
TW (1) TW201932462A (es)
UY (1) UY37947A (es)
WO (1) WO2019081353A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (de) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
WO2023086390A1 (en) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Methods and compositions for providing myocardial protection and treating myocardial stress and fibrosis
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2003008387A1 (en) 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CA2737604C (en) 2008-09-17 2017-08-29 Allergan, Inc. Substituted 3-amino-1-oxo or thioxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles as selective alpha 2b antagonists
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
LT2539326T (lt) 2010-02-27 2017-08-10 Bayer Intellectual Property Gmbh Sujungti bisariliniai ariltriazolonai ir jų panaudojimas
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9000186B2 (en) * 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
SG11201408421TA (en) 2012-07-20 2015-02-27 Bayer Pharma AG Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
WO2014131760A1 (de) * 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
JP6623220B2 (ja) 2014-11-03 2019-12-18 バイエル ファーマ アクチエンゲゼルシャフト ヒドロキシアルキル置換フェニルトリアゾール誘導体およびその使用

Also Published As

Publication number Publication date
DOP2020000072A (es) 2020-08-31
BR112020007967A2 (pt) 2020-10-20
SG11202003641RA (en) 2020-05-28
CR20200173A (es) 2020-06-26
CO2020004968A2 (es) 2020-05-05
CL2020001075A1 (es) 2021-01-22
JOP20200073A1 (ar) 2020-04-29
MX2020004190A (es) 2020-08-03
IL273954A (en) 2020-05-31
KR20200076686A (ko) 2020-06-29
AR113790A1 (es) 2020-06-10
CU20200041A7 (es) 2021-03-11
NI202000029A (es) 2020-10-09
EP3700903A1 (de) 2020-09-02
WO2019081353A1 (de) 2019-05-02
PH12020550472A1 (en) 2021-03-15
ECSP20023043A (es) 2020-06-30
JP2021500366A (ja) 2021-01-07
UY37947A (es) 2019-05-31
CA3084422A1 (en) 2019-05-02
CN111225917A (zh) 2020-06-02
TW201932462A (zh) 2019-08-16
MA50440A (fr) 2020-09-02
AU2018354785A1 (en) 2020-04-23
US20200339567A1 (en) 2020-10-29
EA202091020A1 (ru) 2020-07-24

Similar Documents

Publication Publication Date Title
PE20201280A1 (es) Amidas de imidazopiridina sustituidas y su uso
CL2018000036A1 (es) Derivados etinilo
JP5869484B2 (ja) 架橋複素環化合物およびその使用
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
NI201900060A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
CN106132934B (zh) 治疗炎性病症的苯并咪唑衍生物及其医药组合物
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR050914A1 (es) Agonista receptor de vasopresina peptidico
UY30686A1 (es) "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos"
EA201591204A3 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
PE20220386A1 (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
ES2928246T3 (es) 6-aminopiridin-3-il pirazoles como moduladores de RORyt
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
AR080733A1 (es) Aril-ciclohexil-tetraazabenzo[e]azulenos, un proceso para su obtencion, una composicion farmaceutica que los contiene y su uso para la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el antagonismo del receptor de v1a
CL2020003227A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JP2015502371A5 (es)
RU2016131363A (ru) ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ
AR111176A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
AR099529A1 (es) Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2